Hai Zheng Pharmaceutical Industry was awarded the production of "Tamiflu" intermediate gold analyst recommend

Every reporter Tri Dan yesterday, Hai Zheng Pharmaceutical Industry (600267, closing price of 16.32 Yuan) a bulletin of the company and the "flu concept" linked together. As the National Development and Reform Commission approved the sea is the pharmaceutical production of "Tamiflu" intermediates drugs, for a time the stock by the market funds enthusiastically sought after. Yesterday, the sea is the pharmaceutical industry to open trading price, but then trading board was opened.　　The stock ended at a close of 4.62% per cent. Hai Zheng Pharmaceutical production of "Tamiflu" intermediates announced the announcement, last year, the new wealth of the pharmaceutical industry gold analysts to praise the words, have to the company's future prospects show bullish.　　Wanguo's report even gave it a target price of 24 yuan. Approved "Tamiflu" intermediates in fact, as early as last month, the sea is the pharmaceutical production of "Tamiflu" news. At that time, the market rumors that the sea is the pharmaceutical industry Roche authorized production of "Tamiflu", affected by this message, the two-level market Hai Zheng is unusually eye-catching performance.　　May 14, the unit was sealed to trading, the next day Rose 8.39%. However, on May 15, the company clarified that some of the sites recently circulated "about the company to obtain Roche authorized production Tamiflu" and other relevant information, the company verified that the company does not exist above.　　Then the company's share price fell to a certain extent. But yesterday the company released a national development and Reform Commission approved the production of "Tamiflu" of the intermediates announcement.　　The company announced in the announcement, in order to safeguard the prevention and control of drug supplies, the national Development and Reform Commission approved the Hai Zheng Pharmaceutical Emergency Drug expansion project, will produce other pharmaceutical equipment adaptation phosphoric acid oseltamivir (Tamiflu) intermediates, to ensure the safety of influenza prevention and control drugs supply. "The company's announcement is very artistic, Hai Zheng Pharmaceutical industry does not have Roche's authorization, the production is not Tamiflu." Duffy is the product name of the finished product preparation, and the sea is the pharmaceutical production of raw materials. In this respect, the company is mainly concerned about the failure of technical research, the company's image in the capital market will have a serious impact.　　"A well-known private equity person in China told reporters.　　But the private-equity personage says, the success probability of the technical tackling aspect should be very high, the company obtains the quota production qualification, produces the emergency reserve medicine for the country, this will bring a lasting profit growth point for the company. Gold analysts push the sea is the pharmaceutical industry to become "Tamiflu" intermediate fixed-point manufacturer news by analysts unanimously optimistic.　　Yesterday Wanguo and CIC issued an analysis of the sea's pharmaceutical industry, and the two brokerage Institute's pharmaceutical analysts were the gold analysts of last year's new wealth selection. Wanguo the analyst who issued the report was China and Luo?? Was the first in the pharmaceutical industry, the best analyst for new wealth last year. Shenwan that, compared with many of the market's fried flu concept stocks, a real boost to the performance of the listed companies may only be one of the marine pharmaceutical industry. As Tamiflu is likely to be the country's long-term strategic reserve, researchers estimate that the initial reserve will not be less than tens of millions of people, and that the sea is developing and producing strength that will yield relatively good margins.　　At the same time, Wanguo gave the company 12 months 24 yuan target price. Relative ShenBangwan's optimism, CIC Securities analyst Zhou Rui slightly cautious. In his view, the approval of the project has a positive impact on the marine pharmaceutical industry, but the impact on performance is not yet judged.　　But Zhou Rui still gives the company a "recommendation" rating. However, there are still a number of pharmaceutical industry analysts expressed different views. A brokerage analyst said: "Once the state procurement of the company's gross margin will be very high?" I don't think so, since it's a strategic consideration for the country to make a lot of money. "Then the reporter called Hai Zheng Pharmaceutical industry, the company told reporters:" Gross margin should be relatively low, but the advantage lies in the sale is not a problem. No matter how the epidemic develops, the country will carry out strategic reserves, which will be a stable income growth point for the company. "The caution that money has received for the project is also reflected in the disk." Yesterday, the sea is the pharmaceutical industry opened a trading limit, but the trading board only sealed for 23 minutes, then the stock price will fall sharply. And in the trading board was opened, there are two large sales list, respectively, 5.304 million shares and 1.5303 million shares.